Videos

Experts in the management of breast cancer review clinical trial data using PARP inhibitors in the treatment of BRCA1/2-mutated TNBC.

The panel of experts in breast cancer discusses the treatment options for a patient with systemic progression of HER2+ disease on T-DM1 and no CNS metastases.

Experts in the management of breast cancer discuss the role of tucatinib in patients with brain metastases.

Experts in the management of breast cancer review some treatment considerations surrounding the use of PARP inhibitors in BRCA1/2–positive triple-negative breast cancer.

Elizabeth Mittendorf, MD, PhD, presents the case of a 34-year-old woman with PD-L1–positive triple-negative breast cancer.

Expert hematologist/oncologists provide thoughts on the potential role of PI3K inhibitors in managing R/R FL and MZL, as well as other diseases.

Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, discuss the role of PI3K inhibitor combination therapy and novel agents on the horizon for the treatment of R/R FL and MZL.

Amit Singal, MD, discusses options after surgical resection for patients with hepatocellular carcinoma.

Michael Bishop, MD, discusses the different settings where chimeric antigen receptor T-cell therapy are used.

Joshua K. Sabari, MD, discusses the need for EGFR inhibitors designed specifically to treat patients with EGFR-mutant non–small cell lung cancer and an exon 20 insertion.

Jared Weiss, MD, shares insight into current unmet needs in extensive-stage small cell lung cancer and provides advice to researchers about the importance of clinical trials studying differential treatments and biomarkers.

Expert oncologist Jared Weiss, MD, considers safety and efficacy data from the ATLANTIS study of lurbinectedin in combination with doxorubicin in relapsed small cell lung cancer.

Thought leader in lung cancer, Jared Weiss, MD, reviews safety and efficacy data from the phase 2 basket trial of lurbinectedin in selected advanced solid tumors.

Key opinion leader in thoracic oncology, Jared Weiss, MD, discusses the role of second-line treatment for relapsed ES-SCLC after first-line therapy and maintenance immunotherapy.

Jared Weiss, MD, reviews first-line treatment options for extensive-stage small cell lung cancer and highlights the current standard-of-care regimen: carboplatin, etoposide, and a PD-L1 inhibitor with the possible addition of trilaciclib.

An expert in the management of lung cancer, Jared Weiss, MD, provides an overview of the initial presentation, clinical work-up, treatment, and follow-up of a 64-year-old woman with extensive-stage small cell lung cancer.

Alexey Danilov, MD, a hematologist oncologist at the City of Hope Comprehensive Cancer Center, discusses treatment options for relapsed/refractory chronic lymphocytic leukemia.

Stephen Oh, MD, PhD, discusses the nuances of identifying disease progression vs transformation in patients with essential thrombocythemia.

Experts in essential thrombocythemia review first line treatment options.

Ruben Mesa, MD, and panel discuss the role of molecular profile in treatment decision-making.

Experts in essential thrombocythemia discuss approaches to individualizing therapy.

Dr Stephen Oh discusses risk assessment in patients with essential thrombocythemia.

Stephen Oh, MD, PhD, reviews the case of a 46-year-old female with essential thrombocythemia.

Experts in hematology/oncology review data from the UNITY-NHL trial and share insights on the sequencing of therapies in R/R FL and MZL.

Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, review the tolerability and efficacy of umbralisib in the management of R/R FL and MZL.

Expert hematologist/oncologists comment on the safety profile of PI3K inhibitors when treating R/R FL and MZL and share their approach to managing associated adverse events.

Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, review clinical trial data for idelalisib, copanlisib, and duvelisib and discuss their personal experience using these agents for the management of R/R FL and MZL.

Rajneesh Nath, MD, discusses outcomes for older patients with acute myeloid leukemia.

The panel discusses treatment options and considerations for a 53-year-old woman with PD-L1+ triple-negative breast cancer.

Carey Anders, MD, and Andrew Seidman, MD, share their recommendations for HER2+ breast cancer recurrence within 12 months of HP.